Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.

Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series

(2008) · doi:10.1002/9780470712184 · Cited by 25,048

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402

Variance imputation for overviews of clinical trials with continuous response

Follmann, D. A., Elliott, P., Suh, I., & Cutler, J. A. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90054-q · Cited by 1,391

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group, Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., & Simó, R. (2009) · Diabetologia · doi:10.1007/s00125-009-1472-y · Cited by 835

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 821

Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial

Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Bergenstal, R. M., Wysham, C., MacConell, L., Malloy, J. L., Walsh, B., Yan, P., Wilhelm, K., Malone, J., & Porter, L. E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60590-9 · Cited by 605

The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion

MacDonald, P. E., El-kholy, W., Riedel, M. J., Salapatek, A. M. F., Light, P. E., & Wheeler, M. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s434 · Cited by 590

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Thomsen, A. B., Søndergaard, R. E., & Davies, M. J. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60307-8 · Cited by 587

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes: A Randomized, Controlled Trial

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J. P., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 467

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes

Blevins, T., Pullman, J., Malloy, J., Yan, P., Taylor, K., Schulteis, C., Trautmann, M., & Porter, L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2081 · Cited by 448

Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60406-0 · Cited by 434

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes

Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 424

One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks

Buse, J. B., Drucker, D. J., Taylor, K., Kim, T., Walsh, B., Hu, H., Wilhelm, K., TRAUTMANN, M. E., Shen, L. Z., Porter, L. E., et al. (2010) · Diabetes Care · doi:10.2337/dc09-1914 · Cited by 357

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study

Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

Russell-Jones, D. L., Cuddihy, R. M., Hanefeld, M., Kumar, A., González‐González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2011) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 338

Glucagon-like peptide 1(GLP-1) in biology and pathology

Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288

Editorial

(1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00246-5 · Cited by 280

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.01.015 · Cited by 279

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

Pratley, R. E., Nauck, M. A., Bailey, T. S., Montanya, E., Cuddihy, R. M., Filetti, S., Garber, A. J., Thomsen, A. B., Hartvig, H. B., Davies, M. J., et al. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02656.x · Cited by 251

Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M. (2011) · Diabetes Care · doi:10.2337/dc11-0291 · Cited by 240

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial

Barnett, A. H., Burger, J., Johns, D., Brodows, R. G., Kendall, D. M., Roberts, A., & TRAUTMANN, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 237

The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies

Blonde, L., & Russell-Jones, D. L. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01075.x · Cited by 233

Long‐term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over‐weight metformin‐treated patients with type 2 diabetes mellitus

Ratner, R. E., Maggs, D., Nielsen, L. L., Stonehouse, A. H., Poon, T., Zhang, B., Bicsak, T. A., Brodows, R. G., & Kim, D. D. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00589.x · Cited by 217

An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the future

Madsbad, S., Kielgast, U. L., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

Gallwitz, B., Guzman, J., Dotta, F., Guerci, B., Simó, R., Basson, B. R., Festa, A., Kiljanski, J. I., Sapin, H., TRAUTMANN, M. E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60479-6 · Cited by 164

Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes

Farmer, A. J., Perera, R., Ward, A., Heneghan, C., Oke, J., Barnett, A. H., Davidson, M. B., Guerci, B., Coates, V., Schwedes, U., et al. (2012) · BMJ · doi:10.1136/bmj.e486 · Cited by 156

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

Ratner, R. E., Han, J., Nicewarner, D., Yushmanova, I., Hoogwerf, B. J., & Shen, L. Z. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-22 · Cited by 153

Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

Feinglos, M. N., Saad, M. F., Pi-Sunyer, F. X., An, B., Santiago, O. M., & on behalf of the Liraglutide Dose‐Response Study Group (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01567.x · Cited by 148

Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study

Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01154.x · Cited by 144

Prognostic Value of Home Heart Rate for Cardiovascular Mortality in the General Population: The Ohasama Study

Hozawa (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.06.019 · Cited by 136

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study

Gill, A. M., Hoogwerf, B. J., Burger, J., BRUCE, S. R., MacConell, L., Yan, P., Braun, D. K., Giaconia, J. M., & Malone, J. K. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-6 · Cited by 134

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Wu, Y., Yan, P., Smith, U., Yki-Järvinen, H., Diamant, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.04.024 · Cited by 132

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

Riddle, M. C., Henry, R. R., Poon, T., Bei, Z., Mac, S. M., Holcombe, J. H., Kim, D. D. H., & Maggs, D. G. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.646 · Cited by 127

Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes

Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., & Glass, L. C. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.11.019 · Cited by 127

Exenatide Versus Glibenclamide in Patients with Diabetes

Derosa, G., Maffioli, P., Salvadeo, S. A. T., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., et al. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0141 · Cited by 125

DURATION‐2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once‐weekly exenatide

Wysham, C., Bergenstal, R. M., Malloy, J. L., Yan, P., Walsh, B., Malone, J. K., & Taylor, K. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03301.x · Cited by 119

GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

Griffioen, K. J. S., Wan, R., Okun, E., Wang, X., Lovett-Barr, M. R., Li, Y., Mughal, M. R., Mendelowitz, D., & Mattson, M. P. (2010) · Cardiovascular Research · doi:10.1093/cvr/cvq271 · Cited by 110

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

Fakhoury, W. K. H., LeReun, C., & Wright, D. (2010) · Pharmacology · doi:10.1159/000314690 · Cited by 110

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin

DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., & Glass, L. C. (2010) · Diabetes Care · doi:10.2337/dc09-1521 · Cited by 104

Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans

Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98 · cited 1×

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16‐week, randomized, double‐blind, active control trial *

Yang, W., Chen, L., Ji, Q., Liu, X., Ma, J., Tandon, N., Bhattacharyya, A., Kumar, A., Kim, K.-W., Yoon, K., et al. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01323.x · Cited by 91

Exenatide Twice Daily Versus Premixed Insulin Aspart 70/30 in Metformin-Treated Patients With Type 2 Diabetes

Gallwitz, B., Böhmer, M., Segiet, T., Mölle, A., Milek, K., Becker, B., Helsberg, K., Petto, H., Peters, N., & Bachmann, O. P. (2011) · Diabetes Care · doi:10.2337/dc10-1900 · Cited by 89

Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea

Gao, Y., Yoon, K., Chuang, L., Mohan, V., Ning, G., Shah, S., Jang, H. C., Wu, T.-J., Johns, D., Northrup, J., et al. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.037 · Cited by 87

Association of Average Heart Rate on 24-Hour Ambulatory Electrocardiograms With Incidence of New Coronary Events at 48-Month Follow-Up in 1,311 Patients (Mean Age 81 Years) With Heart Disease and Sinus Rhythm

Aronow, W. S., Ahn, C. W., Mercando, A. D., & Epstein, S. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)90077-6 · Cited by 83

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

Bergenstal, R. M., Lewin, A. J., Bailey, T. S., Chang, D., Gylvin, T., Roberts, V. L., & for the NovoLog Mix-vs.-Exenatide Study Group (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802597951 · Cited by 82

An overview of the pharmacokinetics, efficacy and safety of liraglutide

Bode, B. W. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.12.015 · Cited by 80

Patient‐reported outcomes following treatment with the human GLP‐1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

Bode, B. W., Testa, M. A., MAGWIRE, M. L., Hale, P. M., Hammer, M., Blonde, L., Garber, A. J., & on behalf of the LEAD‐3 Study Group (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01196.x · Cited by 77

A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin

Liutkus, J., Guzmán, J. R., Norwood, P. C., Pop, L., Northrup, J., Cao, D., & TRAUTMANN, M. E. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01251.x · Cited by 74

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients

Derosa, G., Putignano, P., Bossi, A. C., Bonaventura, A., Querci, F., Franzetti, I., Guazzini, B., Testori, G., Fogari, E., & Maffioli, P. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.051 · Cited by 68

Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

Davies, M. J., Pratley, R. E., Hammer, M., Thomsen, A. B., & Cuddihy, R. M. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03074.x · Cited by 60

Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart

Anselmino, M., Öhrvik, J., Rydén, L., & on behalf of the Euro Heart Survey Investigators (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq368 · Cited by 52

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes

Kadowaki, T., Namba, M., Yamamura, A., Sowa, H., Wolka, A. M., & Brodows, R. G. (2009) · Endocrine Journal · doi:10.1507/endocrj.k08e-296 · Cited by 52

Durability of Effects of Exenatide Treatment on Glycemic Control, Body Weight, Systolic Blood Pressure, C-Reactive Protein, and Triglyceride Concentrations

Varanasi, A., Chaudhuri, A., Dhindsa, S., Arora, A., Lohano, T., Vora, M. R., & Dandona, P. (2010) · Endocrine Practice · doi:10.4158/ep10199.or · Cited by 35

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33

Autonomic nervous system‐dependent and ‐independent cardiovascular effects of exendin‐4 infusion in conscious rats

Gardiner, S. M., March, J. E., Kemp, P. A., & Bennett, T. M. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.75 · Cited by 28

Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus

Gustavson, S. M., Chen, D., Somayaji, V. R., Hudson, K. J., Baltrukonis, D. J., Singh, J., Boyden, T. L., & Calle, R. A. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01479.x · Cited by 21

Effects of glucagon-like peptide-1 (7–36) amide on neurohypophysial hormone secretion induced by acute hyperosmotic challenge

Bojanowska, E., & Stempniak, B. (2003) · Neuropeptides · doi:10.1016/s0143-4179(03)00003-9 · Cited by 4

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial

Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors

Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582

Untitled work

Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560

Correspondence to

Ta, H., Rees, K., Effects, E. A., See, L., Uk, C., & Holt, D. T. A. (2012)

Impact of Glp-1RA on Heart Rate, Blood Pressure and Hypertension Among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun, F., Wu, S., Chai, S., Yang, Z., Yu, K., & Zhan, S. (2014) · Value in Health · doi:10.1016/j.jval.2014.08.010 · Cited by 4

Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis

Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304

For peer review only Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta- analysis

Robinson, L. (2012)

Blood pressure‐lowering effects of GLP ‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trials

Wang, B., Zhong, J., Lin, H., Zhao, Z., Yan, Z., He, H., Ni, Y., Liu, D., & Zhu, Z. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12085 · Cited by 225